7 completed, 2 not yet recruiting, 1 recruiting, 1 unknown. 5 Phase 3, 3 Phase 1, 1 Not applicable, 1 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 4, Not yet recruiting 1 |
| Phase 1 | 3 | Completed 2, Recruiting 1 |
| Not applicable | 1 | Unknown 1 |
| Phase 2 | 1 | Completed 1 |
| Phase 4 | 1 | Not yet recruiting 1 |
Follow Autoinjector: new trials by email Literature Review of Autoinjector trials Research Report on Autoinjector
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial Assessing the Effectiveness of Evolocumab in Reducing the Plaque Burden in Participants With Subclinical Atheroma Evolocumab, Routine Lipid Management, Autoinjector - Coronary Artery Disease, Hypercholesterolemia | Phase 4 | Not yet recruiting | Amgen | 308 | 2027-01-31 | 2026-09-21 |
| Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight Maridebart cafraglutide, Autoinjector - Obesity, Overweight | Phase 3 | Not yet recruiting | Amgen | 230 | 2026-10-28 | 2026-10-13 |
| A Trial to Compare the Pharmacokinetics of Two Presentations of Navenibart in Healthy Participants Autoinjector, Vial and syringe - Healthy Adult Participants | Phase 1 | Recruiting | Astria Therapeutics, Inc. | 180 | 2026-04-21 | 2026-06-09 |
| A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED) VRDN-003, Autoinjector - Thyroid Eye Disease | Phase 3 | Completed | Viridian Therapeutics, Inc. | 87 | 2025-07-01 | 2026-06-25 |
| Assessment of Injectable Medication Platforms Autoinjector, Standard Injector, Prefilled - Overdose Antidote, Bleeding | Not applicable | Unknown | Canadian Forces Health Services Centre Ottawa | 30 | 2022-04-30 | 2023-02-08 |
| Accessorized Pre-Filled Syringe to Autoinjector Pharmacokinetic Bridging Study in Anifrolumab Anifrolumab, Autoinjector, Accessorized Pre-Filled Syringe - Healthy Participants Study | Phase 1 | Completed | AstraZeneca | 180 | 2022-03-22 | 2023-05-11 |
| A Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Plaque Psoriasis Risankizumab, Autoinjector - Psoriasis | Phase 3 | Completed | AbbVie | 108 | 2019-06-04 | 2021-05-11 |
| An Multicentre Clinical Study to Evaluate the Usability and Safety of the Autoinjector and Pre-filled Syringe of SB4 in Subjects With Rheumatoid Arthritis Etanercept, Autoinjector - Rheumatoid Arthritis | Phase 2 | Completed | Samsung Bioepis Co., Ltd. | 50 | 2017-05-15 | 2017-10-13 |
| Usability of an AI for M923 in Subjects With Moderate to Severe RA M923, Autoinjector - Rheumatoid Arthritis | Phase 3 | Completed | Momenta Pharmaceuticals, Inc. | 33 | 2016-04-01 | 2018-05-16 |
| A Study of Administration of Peginterferon Alfa-2a [Pegasys] by Autoinjector Versus Pre-filled Syringe in Patients With Chronic Hepatitis C Autoinjector, Pre-filled syringe - Hepatitis C, Chronic | Phase 1 | Completed | Hoffmann-La Roche | 60 | 2010-03-01 | 2016-02-09 |
| Paramedic Treatment of Prolonged Seizures by Intramuscular Versus Intravenous Anticonvulsant Medications Intramuscular route of active treatment, Intravenous route of active treatment - Status Epilepticus | Phase 3 | Completed | Robert Silbergleit | 1023 | 2009-06-01 | 2016-06-17 |
Arthritis, Rheumatoid (2) · Coronary Artery Disease (1) · Graves Ophthalmopathy (1) · Hemorrhage (1) · Hepatitis C, Chronic (1) · Hypercholesterolemia (1) · Hypercholesterolemia, Autosomal Dominant, 3 (1) · Hypersensitivity (1) · Obesity (1) · Overweight (1) · Plaque, Atherosclerotic (1) · Psoriasis (1) · Seizures (1) · Status Epilepticus (1)
Amgen (2) · AbbVie (1) · AstraZeneca (1) · Astria Therapeutics, Inc. (1) · Canadian Forces Health Services Centre Ottawa (1) · Hoffmann-La Roche (1) · Momenta Pharmaceuticals, Inc. (1) · Robert Silbergleit (1) · Samsung Bioepis Co., Ltd. (1) · Viridian Therapeutics, Inc. (1)
United States (8) · Canada (1) · Germany (1) · Poland (1) · United Kingdom (1)
Daniel H Lowenstein, MD (1) · Gaurav Gupta, MD (1) · John Caminis, MD (1) · Robert Silbergleit, MD (1) · Valerie L Durkalski, PhD (1)
PMID 21967361, PMID 22335736, PMID 22506949, PMID 24001080, PMID 31372961, PMID 35987977
U01NS056975 (1)